Objective: Gestational diabetes mellitus (GDM) is a metabolic disorder that shares pathophysiologic features with type 2 diabetes mellitus. The aim of this study was to investigate the association of the polymorphisms fat mass and obesity-associated (FTO) rs1421085, leptin receptor (LEPR) rs1137100, rs1137101, peroxisome proliferator-activated receptor gamma (PPARg) rs1801282, and transcription factor 7-like 2 (TCF7L2) rs7901695 with GDM. Subjects and methods: 252 unrelated Euro-Brazilian pregnant women were classified into two groups according to the 2015 criteria of the American and Brazilian Diabetes Association: healthy pregnant women (n = 125) and pregnant women with GDM (n = 127), matched by age. The polymorphisms were genotyped using fluorescent probes (TaqMan ® ). Results: All groups were in Hardy-Weinberg equilibrium. The genotype and allele frequencies of the studied polymorphisms did not show significant differences between the groups (P > 0.05). In the healthy and GDM groups, the C allele frequencies (95% CI) of the FTO rs1421085 polymorphism were 36.8% [31-43%]
1,5 anhydroglucitol (1,5-AG), is a nonmetabolized 1-deoxy form of glucose, originate mainly from the diet. 1,5-AG is a biomarker to detect and magnify hyperglycemic excursions (postprandial hyperglycemia) in diabetic patients. Concentrations of 1,5-AG has been applied as supporting biomarker to diagnosis of the major forms of diabetes (type 1, type 2, and gestational). The serum 1,5-AG reference interval is relevant to the appropriate clinical application of this biomarker. This article contains data regards to serum concentration of the biomarker primarily for healthy subjects, capture from the literature, in different populations. Correlation analysis between 1,5-AG and markers associated with diabetes and its complication were presented. The data was complementary to the study “Reference intervals for serum 1,5-anhydroglucitol in children, adolescents, adults, and pregnant women” (Welter et al., 2018). The data present in this article improve the comparisons for 1,5-AG in different conditions and methodologies.
O Diabetes Mellitus (DM) é uma síndrome multifatorial cujas complicações matam 5% da população mundial todo ano. A hiperglicemia crôncia característica do DM promove disfunção endotelial e o desenvolvimento de complicações microvasculares, como nefropatia, retinopatia e neuropatia, e macrovasculares como o acidente vascular cerebral e infarto agudo do miocárdio (IAM). O DM é uma patologia com altas taxas de morbidade e mortalidade, o que torna relevante a realização de estudos epidemiológicos para investigar suas características. O objetivo deste trabalho foi analisar o perfil clínico-laboratorial e a presença de complicações vasculares em pacientes com DM tipo 2 (DM2). Foram selecionados 300 pacientes com DM2 atendidos no Serviço de Endocrinologia e Metabologia do Hospital de Clínicas da Universidade Federal do Paraná (HC-UFPR). Dados clínico-laboratoriais foram coletados e analisados a partir do prontuário médico e do banco de dados do laboratório do HC-UFPR. O projeto foi aprovado pelo Comitê de Ética em Pesqusia do Setor de Ciências da Saúde da UFPR (número CAAE: 01038112.0.0000.0102). Os participantes tinham média de idade de 62 anos, eram na maioria mulheres (73%), apresentavam obesidade, hipertensão e dislipidemia. Concentrações de hemoglobina glicada >7%, indicando mal controle glicêmico, foram detectadas em 60,3% dos pacientes com DM2 neste estudo. E 40,7% dos participantes apresentaram ao menos uma complicação vascular. Os dados encontrados reforçam as estatísticas que pacientes com DM2 apresentam hipertensão, dislipidemias e obesidade, e estão em maior risco para complicações vasculares que podem causar morbidade e mortalidade.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.